Are stem-cell cardiomyocytes a viable cellular reagent for automated patch-clamp?


SPS 2017


Michael Morton, Lauren Eades



ICH guidelines state that compounds in drug discovery must be tested for inhibition of hERG cardiac
ion channel. It is often prudent to test compounds against a wider array of cardiac ion channels, e.g.
hNaV1.5 and hCaV1.2 (Kramer et al., 2013). The CiPA initiative will demand testing and additional ion
channel targets as well; namely hNaV1.5 late current, hKir2.1, hKvLQT1 and Kv4.3 (Gintant et al., 2016).
These ion channel assays are all amenable to automated patch-clamp and have typically been run
using recombinant cell lines over-expressing an individual ion channel. The aim of this research was to
investigate whether human induced pluripotent stem cell-derived cardiomyocytes are a useful,
affordable and predictive cellular reagent for use on the QPatch automated patch-clamp system.

Go to journal

Get in Touch

We strive to provide the best for our customers, and we are always ready to help. Please let us know if you have a question for us.

Follow us